This site and the owners of the same do not use cookies. However, the domain hosting service or search engines may use technical cookies for tracing the site.
If you continue in the exploration, you agree to accept the eventual cookies that may refer to the navigation.
INNOVATIVE PHARMACEUTICALS, SUPPLEMENTS AND BY-PRODUCTS
The basic and applied reseach that brought to the final definition of 35 formulations of innovative medicines, supplements and by-products is advanced and finds continuous confirmation in the tests and treatments that are still conducted.
Clinical tests on the effectiveness of the products for the cure of different pathologies have been registered since 1998. The clinical evidence of the cures is summed up in the following list, that underlines the percentage of positivity, the number of treatments and the pathologies:
Positivity of Treatments in Pathologies
98% of 403: Joint sprains, muscle trauma, tendon injuries, algodystrophies, groin, primitive periosteal pains and periosteal pains due to cancer metastasis
95% of 164: Various gonalgies with or without usury of cartilages, posttraumatic hematomas, phlebopathies
100% of 8: Serious inflammatory states of skin, subcutaneously stratums, muscles and articulations
100% of 10: Serious inflammatory venous diseases
92,4% of 66: Peripheral neurogenic pains
100% of 20: Aftereffects of bone fractures
98% of 58: Acne
100% of 7: Rosacea
98% of 31: Atopic dermatitis
100% of 90: Skin burns
94% of 88: Itchy states or insect bites
100% of 20: Herpes simplex or herpes zoster
100% of 35: Hemorrhoids
97% of 118: Gingivitis, stomatitis, dental plaque, pharyngitis, tonsillitis
92% of 76: Dental and gingival pains in adults and children, paradentosis, various odontalgies
100% of 43: Pains before the primary dentition
100% of 66: Ear pains
90% of 56: Muscle cramps during pathologies
100% of 38: Muscle cramps in sportsmen
100% of 64: Energy supplement with amino acids, carbohydrates and other elements
100% of 2: Pathologies connected to lacks of Vitamin D
_______________________________
Between the most important pathologies that have been treated, there are inflammatory states, muscle, tendon, gonalgies and skin diseases. The absorption possibility of determinate pharmacological molecules allows also the treatment of chronic primary polyarthritis.
A key element in the formulation of the different products is the substance that acts as a carrier for the pharmacological molecules: in fact, it allows them to be adsorbed by the human body and it has a notable innovative potential, since otherwise the same molecules would not be transferred to organs and tissues. Therefore, the new formulations do not have equivalents in the market. A the same time, the carrier substance has itself particular properties that have been revealed by the research tests. Among these characteristics, there are the strong antioxidant properties and the inibition of the production of interleukins that cause inflammatory states.
The whole research has obtained the support of universities and research centres during the years. Following, there are the main provisions.
The Laboratory of Pharmacobiochemistry of the Department of Biology and Biotecnologies of the University of Pavia conducted different tests “in vitro” and proved that the carrier substance could reduce the oxidative activity of toxic concentrations of H2O2 on cell cultures and reduce the peroxidation of Fe2+ in a fraction of plasma lipoproteins.
The same Laboratory noted the wearying property of the carrier substance connected to amino acids in a liquid supplement for athletic performances of particular commitment and duration, which reduced also the symptoms of the D.O.M.S. syndrome (Delayed Onset Muscle Syndrome).
The Department of Pharmacology of the University of Pavia executed then different tests on enzymes and cells.
The Laboratory of Pharmacological Biochemistry of the Department of Biology and Biotechnologies of the University of Pavia stated the hypotonic property of the carrier substance with osmolarity tests and with the test of Daland Worthley on red blood cells.
Through the Institute of Bioimaging and Molecular Physiology and through the Institute for the Study of Macromolecules, the Italian National Research Council (CNR – Consiglio Nazionale delle Ricerche) has stated that the the carrier substance has great antioxidant properties. Tests have been conducted with the utilization of an electronic paramagnetic resonance instrument. The same result has been obtained by the company H&D Srl, based in Parma (Italy), through the use of a machinery called Fras 5 for the measurement of oxidative stress.
The Universities of Stockholm and Venice also stated the interesting properties of the carrier substance.
The research centre of Bio Basic Europe S.r.l. executed three tests, stating that the carrier substance:
1) has great antioxidant properties (it reduces the ROS percentage in cell cultures of human keratinocytes exposed to oxidative stress);
2) has a relevant soothing activity, since it is able to reduce the synthesis of interleukins in vitro (it reduces the interleukins production in cell cultures of human keratinocytes in vitro at tested concentration of 1.0 mg/ml);
3) has not cytotoxic effects on fibroblasts in vitro (it has proved not to decrease cell viability at tested concentrations on fibroblasts in vitro with a value of IC50 > 5.0 mg/ml. An IC50 value > 0.5 mg/ml means absence of cytotoxic effect).
_______________________________
The equipment for the production of the carrier substance has already been developed in three types of machineries: manual, semi-automatic and automatic. The engineering of the machineries is simple, as well as the production process.
The method of using the mentioned substance as a carrier for pharmacological molecules and other elements to the human tissues and organs allows finally further developments of formulations, in addition to the ones that have already been completed and tested.
Copyright © All Rights Reserved
